Abstract
The chromane nucleus is common to a plenum of bioactive small molecules where it is frequently oxidized at position 3. Motivated by the importance of this position in conferring efficacy, and the prominence of bioisosterism in drug discovery, an iodine(I)/iodine(III) catalysis strategy to access enantioenriched 3‐fluorochromanes is disclosed (up to 7:93 e.r.). In situ generation of ArIF2 enables the direct fluorocyclization of allyl phenyl ethers to generate novel scaffolds that manifest the stereoelectronic gauche effect. Mechanistic interrogation using deuterated probes confirms a stereospecific process consistent with a type IIinv pathway.
Keywords: chromanes, fluorine, gauche effect, organocatalysis, stereospecificity
An iodine(I)/iodine(III) catalysis strategy to access enantioenriched 3‐fluorochromanes is disclosed (up to 7:93 e.r.). In situ generation of ArIF2 enables the direct fluorocyclization of allyl phenyl ethers to generate novel scaffolds that manifest the stereoelectronic gauche effect. Mechanistic interrogation using deuterated probes confirms a stereospecific process consistent with a type IIinv pathway.
Molecular editing with fluorine is a powerful strategy to realize clinical efficacy whilst mitigating perceived metabolic or toxicological liabilities.1 The flexibility to invert localized partial charge (Hδ+→Fδ−),2 or delete single hydrogen bonds whilst preserving the electronic environment (OH→F)3 has a negligible steric penalty, thus rendering this approach expansive. Fluorine bioisosterism is particularly apposite in molecule classes that are pre‐disposed to oxidation at a specified site, but effective structure optimization is contingent on the synthesis arsenal.4 The venerable chromane nucleus inherent to a spectrum of bioactive drugs and natural products is an exemplar of this synergy. Despite the prevalence of the parent (H) and 3‐hydroxy scaffolds (OH), catalysis‐based strategies to access 3‐fluorochromanes remain sparse. Stoichiometric, racemic routes have been reported that rely on XeF2, bromofluorination, or additions to 3‐fluorobutenone,5 whilst catalytic, enantioselective routes have been reported to generate 3‐fluoro‐4‐spiro‐chromanes. Pertinent examples under the auspices of chiral phase transfer catalysis,6 and phosphoramidate catalyzed bromo‐ and iodocyclizations are noteworthy.7 To complement these elegant solutions, efficient entry to the parent 3‐fluorochromane scaffold is needed to complete the bioisosterism continuum [H≈F≈OH] (Figure 1, center)8 and explore the potential of the unsubstituted ring system in drug discovery. The vicinal relationship of fluorine to the ring oxygen will result in stabilizing hyperconjugative interactions (σC‐H→σC‐F*),9 that manifest themselves in the conformation of these drug modules. The broad spectrum of biological activities mediated by chromanes is a powerful motivator to address this deficiency in contemporary catalysis. Pertinent examples include the antidiabetic agent Englitazone (1),10 Xiamenmicin (2) which exhibits anti‐inflammatory properties,11 and the venerable antioxidant Tocopherol (vitamin E) (3).12 The chemotherapeutic potential of (+)‐Catechin (4)13 further adds to this clinical diversity (Figure 1, top). To reconcile the clinical importance of chromanes, and the potential of bioisosterism, with the value of catalysis‐based strategies to access enantioenriched 3‐fluoro scaffolds, a formal 6‐endo‐trig fluorocyclization14, 15 of simple allyl phenyl ethers via II/IIII catalysis16 was envisaged (Figure 1, bottom). This conceptually simple entry point would likely accelerate investigation of the physicochemical profile inherent to this intriguing 3D drug module.17
Figure 1.
Bioactive chromanes, and a catalysis‐based strategy to enable the synthesis of fluorinated systems.
The oxidative functionalization of π‐bonds through hypervalent iodine‐based catalysis platforms has been intensively pursued.18 Contemporaneous reports by this laboratory19 and the Jacobsen laboratory20 have demonstrated that simple aryl iodide/ HF combinations efficiently support the difluorination of alkenes in the presence of a stoichiometric oxidant. Enabled by the in situ generation of hypervalent ArIIIIF2 intermediates,21 these transformations have also been translated to an enantioselective paradigm22, 23 using C 2‐symmetric Ishihara–Muñiz scaffolds.24 Encouraged by the effectiveness of this platform the fluorocyclization of simple 1‐(allyloxy)‐4‐bromobenzene (5) was explored as described in Table 1. The bromo‐substrate was specifically chosen to enable downstream functionalization by cross coupling technologies, and mitigate catalyst sequestration.25 Reactions were performed in dichloromethane at ambient temperature using an initial amine:HF ratio of 1:5 (please see Table 2). Selectfluor® was employed as a terminal oxidant and reactions were quenched after 24 h. A process of catalyst structural editing was performed on a generic C 2‐symmetric iodoresorcinol derivative functionalized with methyl lactate groups (Table 1, entry 1). Although this catalyst scaffold enabled the fluorocyclization of 5 to 6, the product was racemic and formation of the vicinal difluoride 6 a was detected. To enhance catalyst performance, the terminal methyl esters were initially modified. Substituting the methyl esters (X=OMe to OBn) did not translate to an enhancement of selectivity (Table 1, entry 2). However, repeating this at position “R” proved to be encouraging, resulting in an enhanced e.r. from 56:44 to 24:76 (Table 1, entry 3).
Table 1.
Catalyst optimization.[a]
Entry |
Y |
R |
X |
Yield [%] (6:6 a)[b] |
e.r. (6) |
---|---|---|---|---|---|
1 |
H |
H |
OMe |
47 (91:9) |
52:48 |
2 |
H |
H |
OBn |
48 (89:11) |
56:44 |
3 |
H |
Ph |
OMe |
51 (93:7) |
24:76 |
4[c] |
H |
Ph |
OMe |
56 (90:10) |
38:62 |
5 |
H |
Ph |
NHMe |
72 (93:7) |
13:87 |
6[c] |
H |
Ph |
NHMe |
69 (93:7) |
27:73 |
7 |
H |
Ph |
NH2 |
72 (93:7) |
12:88 |
8 |
H |
Ph |
NMe2 |
71 (89:11) |
34:66 |
9 |
H |
Cy |
NHMe |
47 (90:10) |
28:72 |
10 |
Me |
Ph |
NHMe |
60 (92:8) |
12:88 |
11 |
CO2Me |
Ph |
NHMe |
60 (93:7) |
12:88 |
[a] Standard reaction conditions: 5 (0.2 mmol), catalyst (20 mol %), Selectfluor® (1.5 equiv), solvent (0.5 mL), amine:HF 1:5 (0.5 mL), ambient temperature, 24 h. [b] Determined by 19F NMR spectroscopy of the crude reaction mixture using ethyl fluoracetate as internal standard. [c] C 1‐symmetric catalyst.
Table 2.
Reaction optimization.[a]
Entry |
Oxidant |
Amine:HF |
Solvent |
Yield [%] (6:6 a)[b] |
e.r. (6) |
---|---|---|---|---|---|
1 |
Selectfluor® |
1:4.5 |
CH2Cl2 |
52 (87:13) |
12:88 |
2 |
Selectfluor ® |
1:5 |
CH2Cl2 |
72 (93:7) |
13:87 |
3 |
Selectfluor® |
1:6 |
CH2Cl2 |
54 (95:5) |
13:87 |
4 |
Selectfluor® |
1:7.5 |
CH2Cl2 |
19 (100:0) |
18:82 |
5 |
Selectfluor® |
1:5 |
C2H4Cl2 |
64 (90:10) |
13:87 |
6 |
Selectfluor® |
1:5 |
CHCl3 |
66 (91:9) |
14:86 |
7 |
Selectfluor® |
1:5 |
toluene |
52 (90:10) |
15:85 |
8 |
Selectfluor® |
1:5 |
CH3CN |
22 (77:23) |
11:89 |
9 |
m‐CPBA |
1:5 |
CH2Cl2 |
55 (88:12) |
29:71 |
10 |
gr. Oxone |
1:5 |
CH2Cl2 |
16 (66:34) |
13:87 |
11[c] |
Selectfluor® |
1:5 |
CH2Cl2 |
62 (92:8) |
14:86 |
12[d] |
Selectfluor® |
1:5 |
CH2Cl2 |
5 (>95:5) |
–:– |
13[e] |
Selectfluor® |
1:5 |
CH2Cl2 |
<5 (–:–) |
–:– |
[a] Standard reaction conditions: 5 (0.2 mmol), catalyst 7 (20 mol %), Selectfluor® (1.5 equiv), solvent (0.5 mL), amine:HF 1:5 (0.5 mL), ambient temperature, 24 h. [b] Combined yield for 6 and 6 a determined by 19F NMR spectroscopy of the crude reaction mixture using ethyl fluoracetate as internal standard. [c] 10 mol % of 7. [d] 0 °C. [e] Reaction in the absence of catalyst 7.
As a control experiment to validate the importance of C 2‐symmetry, the C 1‐analog was evaluated which gave an e.r. of 38:62 (Table 1, entry 4). To explore the potential of intramolecular hydrogen bonds in pre‐organizing the intermediate IIII species, incorporation of secondary amine units was then explored.26 This led to a notable increase in yield from 51 % to 72 % and e.r. from 24:76 to 13:87 when using the methyl amide‐containing catalyst (Table 1, entries 3 and 5). Again, the C 1‐symmetric control catalyst was prepared and, whilst this led to an improvement in yield and enantioselection compared to the ester (Table 1, entries 4 and 6), the requirement for C 2‐symmetry is clearly apparent (Table 1, entries 5 and 6). The primary amide catalyst (Table 1, entry 7) displayed similar activity, whereas dimethylation (Table 1, entry 8) caused a notable drop in e.r. To explore the possible involvement of non‐covalent aromatic interactions in catalysis,27 the peripheral substituent R was replaced by a cyclohexyl motif (Table 1, entry 9). This proved to be highly detrimental to efficiency (47 % yield versus 72 %). Since the para‐position on the iodoarene provides a handle to regulate the II/IIII oxidation,21a editing at this site was systematically investigated. Although the introduction of a 4‐methyl or methyl ester substituent had no discernible impact on enantioselectivity, a substantial erosion of the overall yield was observed (Table 1, entries 10 and 11).
The remainder of the study was conducted with catalyst 7 (X=NHMe, R=Ph, Y=H). It was possible to obtain crystals of the 4‐methyl‐substituted catalyst that were suitable for X‐ray structure analysis (Figure 2). Salient features of this analysis include the shielding influence of the pendant aryl rings above the iodine center, and the direction of the N−H bonds that would conceivably enable intramolecular interactions in the IIII species.
Figure 2.
X‐ray analysis of the 4‐methyl‐substituted catalyst (X=NHMe, R=Ph, Y=Me). Deposition number 199518 contain(s) the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
In the context of our alkene difluorination studies, we established the importance of Brønsted acidity in regulating regio‐selectivity (geminal versus vicinal) in II/IIII catalysis.19b, 22 Whereas lower amine:HF ratios (ca. 1:4.5) favored 1,2‐difluorination of terminal alkenes, Olah's reagent (ca. 1:9 pyridine:HF) induced engagement of the aryl ring leading to the 1,1‐product. In an effort to suppress competing 1,2‐difluorination and facilitate cyclization, the effect of the amine:HF ratio, as a mixture of triethylamine trihydrofluoride and Olah′s reagent, was investigated (Table 2).
As indicated in entries 1—4 in Table 2, a ratio of 1:5 proved optimal (e.r. 13:87). An examination of reaction media revealed chlorinated solvents to suitable (Table 2, entries 5–8), whilst Selectfluor® was found to be the most effective oxidant (Table 2, entries 9 and 10). Lowering catalyst loading to 10 mol % was well tolerated (Table 2, entry 11), but reactivity was suppressed at 0 °C (Table 2, entry 12). Finally, the control experiment in the absence of catalyst supports the notion of an II/IIII cycle (Table 2, entry 13).
Prior to exploring substrate scope, it was desirable to identify potential trends that would link substrate structural features or Brønsted acidity with enantioselection. To that end, electronically diverse aryl allyl ethers were subjected to the optimized reaction conditions given in Table 2 (Figure 3).
Figure 3.
Strategy to evaluate Brønsted acid effect.
A plot of the Hammett σ p + value against the log e.r. revealed that enantioselectivity is essentially substituent independent, which bodes well for scope expansion (Figure 4 a). As expected, however, the amine:HF ratio plays a crucial role in the relay of the chiral information (Figure 4 b) Whereas lower Brønsted acidities (1:4.5 to 1:5) induce more favorable e.r values, higher ratios (up to 1:9.2) compromise chiral induction.
Figure 4.
Effect of arene electron‐density and Brønsted acidity on enantioinduction.
Plotting the yield against the σ p + value for defined amine:HF ratios served an important practical purpose in allowing individual substrate optimization (Figure 5 a). The optimized amine:HF ratio of 1:5 is evident from Figure 5 b with the exception of the para‐nitro derivative where a ratio of 1:9.2 proved to be optimal. It is pertinent to note that the effect of deactivating groups under HF/SbF5 super‐acid conditions has been shown to influences the relative stabilities of the Wheland intermediates.28
Figure 5.
Effect of arene electron‐density and Brønsted acidity on yield.
These data indicate that synthetically useful levels of efficiency will only be reached for the most electron‐withdrawing systems (e.g. CN, NO2, CHO) under increased Brønsted acidic conditions. It logically follows that this will negatively impact on enantioselectivity. To enable the generation of diversely functionalized chromanes, two fluorocyclization protocols were established: Method A with an amine:HF ratio of 1:5, and Method B with a 1:7.5 ratio. Using Method A, 6‐bromo‐3‐fluorochromane (6) could be isolated in a synthetically useful yield of 55 % with an e.r. of 13:87 (Scheme 1). The halogen series showed similar results with the 3‐fluoro‐6‐chloro‐ (8) and 3,6‐difluoro‐chromanes (9) being isolated in 56 % and 44 % yield (e.r. 11:89 and 12:88, respectively).
Scheme 1.
Exploring the scope of the reaction. Standard reaction conditions: allyl aryl ether (0.5 mmol), 7 (20 mol %), Selectfluor® (1.5 equiv), CH2Cl2 (1.25 mL), amine:HF 1:5 (Method A) or 1:7.5 (Method B) (1.25 mL), ambient temperature, 24 h. Isolated yield of the chromane is indicated.
Exposing meta‐disubstituted phenyl allyl ethers to Method A provided the dibrominated and dichlorinated compounds 10 and 11 in similar yields (51 % and 59 %) and with enantiomeric ratios of 7:93 and 8:92, respectively. In contrast, the regioisomeric ortho‐meta‐dichlorinated phenyl ether furnished the desired chromane 12 with significant erosion of both yield and e.r. (29 %, 30:70). Mesylation of 4‐(allyloxy)phenol and subsequent fluorocyclization was an efficient strategy to access 13 in 67 % yield and 16:84 e.r. with the electron sink supressing formation of a potential charge‐transfer complex.29 In stark contrast the 4‐methoxy derivative proved recalcitrant to cyclization (see Scheme 2, 22). The methyl ester 14 could be isolated in 57 % with an e.r. of 10:90 using amine:HF 1:5. When using amine:HF 1:7.5, the e.r. dropped to 19:81 albeit with a slight improvement in yield (63 %). The increased acidity proved crucial for phenyl ketone 15 (39 % using method A to 55 % using method B). Additional electron‐deficient substrates could also be processed to the corresponding chromanes, including the trifluoromethyl‐analog 16, nitrile 17 and sulfone 18 (up to 57 % yield, up to 16:84 e.r.). A representative benzaldehyde derivative was compatible with the catalysis protocol, to furnish 19 with an e.r. of 20:80. The nitro derivatives 20 was isolated in 44 % yield and 17:83 e.r., thereby providing potential entry into amino‐chromanes.30 Exposure of an isobutene substrate to Method A generated chromane 21 in 51 %, but with complete loss of chiral information (45:55 e.r.). Taken together with the striking differences in enantioselection observed with regioisomers 11 and 12, it is evident that the highly pre‐organized IIII intermediate is susceptible to subtle structural changes.
Scheme 2.
Control experiments. Standard reaction conditions: allyl aryl ether (0.2 mmol), 7 (20 mol %), Selectfluor® (1.5 equiv), CH2Cl2 (0.5 mL), amine:HF 1:5 or 1:7.5 (0.5 mL), ambient temperature, 24 h. Yield determined by 19F NMR spectroscopy of the crude reaction mixture using ethyl fluoroacetate as internal standard.
Gratifyingly, derivative 21, together with 17 and 20 were crystalline and it was possible to unequivocally establish structure by X‐ray analyses (Figure 6). In the case of 17 and 20, the new C(sp3)−F center was determined to be (R)‐configured (Figure 6). Moreover, the solid‐state structures of 17 and 20 adopt a half‐chair conformation in which the stereoelectronic gauche effect manifests itself (σC‐H→σ*C‐F). Torsion angles of (ΦFCCO) of −66.2° and −62.2° were determined in which the fluorine substituent is pseudo‐axial and antiperiplanar to neighboring donor orbitals (i.e. σC‐H bonds). In the racemic product 21, a similar half‐chair conformation is observed with the methyl substituent pseudo‐equatorial. The alignment of the pseudo‐axial C(sp3)−F bond with three σC‐H bonds is a conspicuous feature. In all cases, the donor C(sp3)−H/CH3 bonds on the fluorine‐bearing carbon are antiperiplanar to the ring C(sp3)−O thereby fulfilling the stereoelectrionic requirements of this effect.9
Figure 6.
Deposition numbers 1995719 (for 17), 1995720 for (for 20) and 1995721 (for 21) contain(s) the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.
To further establish the scope and limitations of the reaction, and lend support to the working hypothesis, a series of control experiments were conducted (Scheme 2). As previously indicated, the electron rich p‐OMe derivative 22 was not compatible with these conditions (23, <5 %).31 Attempts to substitute the ether linker by a thioether, such as 24, or by an amine (e.g. 26) were unsuccessful (<5 %). In the case of 26, efficient vicinal difluorination was observed (27, 60 %). To discount the possibility of an in situ Claisen rearrangement/ fluorocyclization sequence giving rise to the target 3‐fluorochromane, substrate 29 was converted to 30. Exposure to the general catalysis conditions did not generate the product 8 with the efficiency described in Scheme 1 (Method A: 56 %).
Finally, to interrogate stereospecificity in the title fluorocyclization, the deuterated Z‐ and E‐configured alkenes 30 and 31 were prepared (Scheme 3). Upon independently exposing these substrates to the general conditions using catalyst 7 (please see the Supporting Information), 30 was smoothly converted to 32, whereas 31 was processed to 33. The coupling constants 3 J FD and 3 J FH a, revealed the relative anti‐configuration for 32 (derived from the Z‐alkene 30) with a large 3 J FD of 5.3 Hz (equivalent to a 3 J FH of 34.5 Hz) and a small 3 J FH a of 16.7 Hz. By comparison, the syn‐configured chromane 33 displayed a small 3 J FD of 2.3 Hz (equivalent to a 3 J FH of 15.0 Hz) and a larger 3 J FH a of 35.4 Hz.32 This analysis was conducted with both the (R,R)‐catalyst and the (S,S)‐catalyst for completeness.
Scheme 3.
Exploring stereospecificity with deuterated probes.
The stereospecific relay of information [Z→anti and E→syn] allow this transformation to be characterized according to the nomenclature established by Denmark and co‐workers for vicinal dihalogenation reactions.33 It is conceivable that the fluorocyclization of aryl allyl ethers under the auspices of II/IIII catalysis might follow a type IIinv pathway (Scheme 4).
Scheme 4.
A tentative catalytic cycle and induction model invoking a type IIinv pathway.
Initially, Selectfluor®‐mediated oxidation of catalyst 7 enables in situ formation of the transient difluoro(aryl)‐λ3‐iodane I in which H‐bonding is important in orchestrating induction (please see Table 1, entries 3 and 5). Ligand exchange at the iodine center with the substrate alkene and concomitant cyclization (II) is likely pre‐organized by stabilizing aromatic interactions. This is supported by the results disclosed in Table 1, entries 5 and 9. Nucleophilic displacement (III) and closure of the catalytic cycle provides a rationale for the relative syn‐configuration and stereospecificity that was determined by detailed NMR analysis (31→33).
In conclusion, an operationally simple, direct fluoro‐cyclization of aryl allyl ethers to access biologically relevant enantio‐enriched 3‐fluorochromanes is disclosed. Selectivities up to 7:93 e.r. can be obtained using a simple C 2‐symmetric iodoresorcinol catalyst in combination with Selectfluor® and simple amine:HF combinations. X‐ray crystallographic analyses of representative products reveal conformations that enable stabilizing stereoelectronic interactions. This physicochemical consideration renders these materials potentially valuable as drug discovery modules. Mechanistic interrogation of the reaction using deuterated probes reveals that the process is stereospecific and likely follows a type IIinv pathway.
Experimental Section
Full details are provided in the Supporting Information.
Conflict of interest
The authors declare no conflict of interest.
Supporting information
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Supplementary
Acknowledgements
We acknowledge generous financial support from the WWU Münster and the German Research Council/ Deutsche Forschungsgemeinschaft (DFG; SFB 858).
J. C. Sarie, C. Thiehoff, J. Neufeld, C. G. Daniliuc, R. Gilmour, Angew. Chem. Int. Ed. 2020, 59, 15069.
In memory of Prof. Dr. Kilian Muñiz (1970–2020).
References
- 1.
- 1a. Purser S., Moore P. R., Swallow S., Gouverneur V., Chem. Soc. Rev. 2008, 37, 320–330; [DOI] [PubMed] [Google Scholar]
- 1b. O'Hagan D., J. Fluorine Chem. 2010, 131, 1071–1081; [Google Scholar]
- 1c. Gillis E. P., Eastman J. K., Hill M. D., Donnelly D. J., Meanwell N. A., J. Med. Chem. 2015, 58, 8315–8359; [DOI] [PubMed] [Google Scholar]
- 1d. Meanwell N. A., J. Med. Chem. 2018, 61, 5822–5880. [DOI] [PubMed] [Google Scholar]
- 2.
- 2a. O'Hagan D., Chem. Soc. Rev. 2008, 37, 308–319; [DOI] [PubMed] [Google Scholar]
- 2b. Zimmer L. E., Sparr C., Gilmour R., Angew. Chem. Int. Ed. 2011, 50, 11860–11871; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2011, 123, 12062–12074; [Google Scholar]
- 2c. Aufiero M., Gilmour R., Acc. Chem. Res. 2018, 51, 1701–1710. [DOI] [PubMed] [Google Scholar]
- 3. Böhme H.-J., Banner D., Kansy M., Kuhn B., Müller K., Obst-Sander U., Stahl M., ChemBioChem 2004, 5, 637–643. [DOI] [PubMed] [Google Scholar]
- 4. Liang T., Ritter T., Angew. Chem. Int. Ed. 2013, 52, 8214–8264; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2013, 125, 8372–8423. [Google Scholar]
- 5.
- 5a. Zajc B., Zupan M., J. Org. Chem. 1990, 55, 1099–1102; [Google Scholar]
- 5b. Haufe G., Wessel U., Schulze K., Alvernhe G., J. Fluorine Chem. 1995, 74, 283–291; [Google Scholar]
- 5c. Patrick T. B., Dahal U. P., J. Fluorine Chem. 2009, 130, 470–473. [Google Scholar]
- 6.
- 6a. Rauniyar V., Lackner A. D., Hamilton G. L., Toste F. D., Science 2011, 334, 1681–1684; [DOI] [PubMed] [Google Scholar]
- 6b. Romanov-Michailidis F., Guénée L., Alexakis A., Angew. Chem. Int. Ed. 2013, 52, 9266–9270; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2013, 125, 9436–9440; [Google Scholar]
- 6c. Romanov-Michailidis F., Romanova-Michaelides M., Pupier M., Alexakis A., Chem. Eur. J. 2015, 21, 5561–5583. [DOI] [PubMed] [Google Scholar]
- 7. Lu Y., Nakatsuji H., Okumura Y., Yao L., Ishihara K., J. Am. Chem. Soc. 2018, 140, 6039–6043. [DOI] [PubMed] [Google Scholar]
- 8. Shen H. C., Tetrahedron 2009, 65, 3931–3952. [Google Scholar]
- 9.
- 9a. Thiehoff C., Rey Y. P., Gilmour R., Isr. J. Chem. 2017, 57, 92–100; [Google Scholar]
- 9b. Molnár I. G., Thiehoff C., Holland M. C., Gilmour R., ACS Catal. 2016, 6, 7167–7173; [Google Scholar]
- 9c. Scheidt F., Selter P., Santschi N., Holland M. C., Dudenko D. V., Daniliuc C. D., Mück-Lichtenfeld C., Hansen M. R., Gilmour R., Chem. Eur. J. 2017, 23, 6142–6149. [DOI] [PubMed] [Google Scholar]
- 10. Valsamakis G., Kumar S., Exp. Opin. Pharmacother. 2000, 1, 1413–1421. [DOI] [PubMed] [Google Scholar]
- 11.
- 11a. Xu M.-J., Lui X.-J., Zhao Y.-L., Lui D., Xu Z.-H., Lang X. M.-, Ao P., Lin W.-H., Yang S.-L., Zhang Z.-G., Xu J., Mar. Drugs 2012, 10, 639–654; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11b. Liu X.-J., Xu M.-J., Fan S.-T., Wu Z., Li J., Yang X.-M., Wang Y.-H., Xu J., Zhang Z.-G., J. Invest. Dermatol. 2013, 133, 1351–1360; [DOI] [PubMed] [Google Scholar]
- 11c. Jiao X., Yao Y., Yang B., Lui X., Li X., Yang H., Li L., Xu J., Xu M., Xie P., Org. Biomol. Chem. 2016, 14, 1805–1813. [DOI] [PubMed] [Google Scholar]
- 12. Brigelius-Flohé R., Traber M. G., FASEB J. 1999, 13, 1145–1155. [PubMed] [Google Scholar]
- 13. Weyant M. J., Carothers A. M., Dannenberg A. J., Bertagnolli M. M., Cancer Res. 2001, 61, 118–125. [PubMed] [Google Scholar]
- 14.For selected examples of catalytic fluorocyclizations via II/IIII catalysis, see
- 14a. Suzuki S., Kamo T., Fukushi K., Hiramatsu T., Tokunaga E., Dohi T., Kita Y., Shibata N., Chem. Sci. 2014, 5, 2754–2760; [Google Scholar]
- 14b. Woerly E. M., Banick S. M., Jacobsen E. N., J. Am. Chem. Soc. 2016, 138, 13858–13861; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14c. Kitamura K., Miyake A., Muta K., Oyamada J., J. Org. Chem. 2017, 82, 11721–11726; [DOI] [PubMed] [Google Scholar]
- 14d. Mennie K. M., Banik S. M., Reichert E. C., Jacobsen E. N., J. Am. Chem. Soc. 2018, 140, 4797–4802; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14e. Scheidt F., Thiehoff C., Yilmaz G., Meyer S., Daniliuc C. G., Kehr G., Gilmour R., Beilstein J. Org. Chem. 2018, 14, 1021–1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.For selected stoichiometric fluorocyclizations with IIII reagents, see:
- 15a. Sawaguchi M., Hara S., Yoneda N., J. Fluorine Chem. 2000, 105, 313–317; [Google Scholar]
- 15b. Kong W., Feige P., de Haro T., Nevado C., Angew. Chem. Int. Ed. 2013, 52, 2469–2473; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2013, 125, 2529–2533; [Google Scholar]
- 15c. Geary G. C., Hope E. G., Stuart A. M., Angew. Chem. Int. Ed. 2015, 54, 14911–14914; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2015, 127, 15124–15127; [Google Scholar]
- 15d. Yuan W., Szabó K. J., Angew. Chem. Int. Ed. 2015, 54, 8533–8537; [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew. Chem. 2015, 127, 8653–8657; [Google Scholar]
- 15e. Brunner C., Andries-Ulmer A., Kiefl G. M., Gulder T., Eur. J. Org. Chem. 2018, 2615–2621; [Google Scholar]
- 15f. Zhang J., Szabó K. J., Himo F., ACS Catal. 2017, 7, 1093–1100; [Google Scholar]
- 15g. Li L., Cao S., Lin F., Liao P., Ning Y., Eur. J. Org. Chem. 2020, 693–696. [Google Scholar]
- 16.
- 16a. Kohlhepp S. V., Gulder T., Chem. Soc. Rev. 2016, 45, 6270–6288; [DOI] [PubMed] [Google Scholar]
- 16b. Arnold A. M., Ulmer A., Gulder T., Chem. Eur. J. 2016, 22, 8728–8739. [DOI] [PubMed] [Google Scholar]
- 17.
- 17a. Huchet Q. A., Kuhn B., Wagner B., Kratochwil N. A., Fischer H., Kansy M., Zimmerli D., Carreira E. M., Müller K., J. Med. Chem. 2015, 58, 9041–9060; [DOI] [PubMed] [Google Scholar]
- 17b. Erdeljac N., Kehr G., Ahlqvist M., Knerr L., Gilmour R., Chem. Commun. 2018, 54, 12002–12005; [DOI] [PubMed] [Google Scholar]
- 17c. O′Hagan D., Chem. Eur. J. 2020, 10.1002/chem.202000178. [DOI] [Google Scholar]
- 18.
- 18a. Yoshimura A., Zhdankin V. V., Chem. Rev. 2016, 116, 3328–3435; [DOI] [PubMed] [Google Scholar]
- 18b. Lee J. H., Choi S., Hong K. B., Molecules 2019, 24, 2634–2656; [Google Scholar]
- 18c. Parra A., Chem. Rev. 2019, 119, 12033–12088. [DOI] [PubMed] [Google Scholar]
- 19.
- 19a. Molnár I. G., Gilmour R., J. Am. Chem. Soc. 2016, 138, 5004–5007; [DOI] [PubMed] [Google Scholar]
- 19b. Scheidt F., Neufeld J., Schäfer M., Thiehoff C., Gilmour R., Org. Lett. 2018, 20, 8073–8076. [DOI] [PubMed] [Google Scholar]
- 20. Banik S. M., Medley J. W., Jacobsen E. N., J. Am. Chem. Soc. 2016, 138, 5000–5003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.
- 21a. Sarie J. C., Thiehoff C., Mudd R. J., Daniliuc C. G., Kehr G., Gilmour R., J. Org. Chem. 2017, 82, 11792–11798; [DOI] [PubMed] [Google Scholar]
- 21b. Sarie J. C., Neufeld J., Daniliuc C. G., Gilmour R., ACS Catal. 2019, 9, 7232–7237. [Google Scholar]
- 22. Scheidt F., Schäfer M., Sarie J. C., Daniliuc C. G., Molloy J. J., Gilmour R., Angew. Chem. Int. Ed. 2018, 57, 16431–16435; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2018, 130, 16669–16673. [Google Scholar]
- 23.
- 23a. Banik S. M., Medley J. W., Jacobsen E. N., Science 2016, 353, 51–54; [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23b. Haj M. K., Banik S. M., Jacobsen E. N., Org. Lett. 2019, 21, 4919–4923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.
- 24a. Fujita M., Yoshida Y., Miyata K., Wakisaka A., Sugimura T., Angew. Chem. Int. Ed. 2010, 49, 7068–7071; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2010, 122, 7222–7225; [Google Scholar]
- 24b. Haubenreisser S., Wöste T. H., Martínez C., Ishihara K., Muñiz K., Angew. Chem. Int. Ed. 2016, 55, 413–417; [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew. Chem. 2016, 128, 422–426; [Google Scholar]
- 24c. Muñiz K., Barreiro L., Romero R. M., Martinez C., J. Am. Chem. Soc. 2017, 139, 4354–4357. [DOI] [PubMed] [Google Scholar]
- 25.For selected examples, see:
- 25a. Bielawski M., Zhu M., Olofsson B., Adv. Synth. Catal. 2007, 349, 2610–2618; [Google Scholar]
- 25b. Bielawski M., Olofsson B., Chem. Commun. 2007, 2521–2523; [DOI] [PubMed] [Google Scholar]
- 25c.for formation of the chromanyl(phenyl)-λ3-iodanes, see: Miyamoto K., Hirobe M., Saito M., Shiro M., Ochiai M., Org. Lett. 2007, 9, 1995–1998. [DOI] [PubMed] [Google Scholar]
- 26.
- 26a. Uyanik M., Yasui T., Ishihara K., Angew. Chem. Int. Ed. 2010, 49, 2175–2177; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2010, 122, 2221–2223; [Google Scholar]
- 26b. Uyanik M., Yasui T., Ishihara K., Angew. Chem. Int. Ed. 2013, 52, 9215–9218; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2013, 125, 9385–9388. [Google Scholar]
- 27. Zhou B., Haj M. K., Jacobsen E. N., Houk K. N., Xue X.-S., J. Am. Chem. Soc. 2018, 140, 15206–15218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.
- 28a. Compain G., Martin-Mingot A., Frapper G., Bachmann C., Jouannetaud M.-P., Thibaudeau S., Chem. Commun. 2012, 48, 5877–5879; [DOI] [PubMed] [Google Scholar]
- 28b. Compain G., Bonneau C., Martin-Mingot A., Thibaudeau S., J. Org. Chem. 2013, 78, 4463–4472. [DOI] [PubMed] [Google Scholar]
- 29.
- 29a. Arisawa M., Ramesh N. G., Nakajima M., Tohma H., Kita Y., J. Org. Chem. 2001, 66, 59–65; [DOI] [PubMed] [Google Scholar]
- 29b. Kita Y., Tohma H., Hatanaka K., Takada T., Fujita S., Mitoh S., Sakurai H., Oka S., J. Am. Chem. Soc. 1994, 116, 3684–3691. [Google Scholar]
- 30. Hodgetts K. J., Kieltyka A., Brodbeck R., Tran J. N., Wasley J. W. F., Thurkauf A., Bioorg. Med. Chem. 2001, 9, 3207–3213. [DOI] [PubMed] [Google Scholar]
- 31.For an example of the electrophilic fluorination of electron rich aromatics with Selectfluor®, see: Banks R. E., Besheesh M. K., Mohialdin-Khaffaf S. N., Sharif I., J. Chem. Soc. Perkin Trans. 1 1996, 2069–2076. [Google Scholar]
- 32. Bucher C., Gilmour R., Angew. Chem. Int. Ed. 2010, 49, 8724–8728; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2010, 122, 8906–8910. [Google Scholar]
- 33. Cresswell A. J., Eey S. T.-C., Denmark S. E., Angew. Chem. Int. Ed. 2015, 54, 15642–15682; [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew. Chem. 2015, 127, 15866–15909. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re‐organized for online delivery, but are not copy‐edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Supplementary